Targeted Therapy
Approved for: NSCLC
Biomarker: ALK

Alectinib (Alecensa) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body).

.

Related Research News

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC

Clinical Research Demonstrates Positive Impact of Genomic Testing for Patients with Non-Small Cell Lung Cancer

Clinical Research Demonstrates Positive Impact of Genomic Testing for Patients with Non-Small Cell Lung Cancer

A Multicenter Study on the Efficacy of Immunotherapy in Advanced Lung Cancer Patients

A Multicenter Study on the Efficacy of Immunotherapy in Advanced Lung Cancer Patients